See more : PT Capitalinc Investment Tbk (MTFN.JK) Income Statement Analysis – Financial Results
Complete financial analysis of ESSA Bancorp, Inc. (ESSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ESSA Bancorp, Inc., a leading company in the Banks – Regional industry within the Financial Services sector.
You may be interested
- Sinomag Technology Co., Ltd. (300835.SZ) Income Statement Analysis – Financial Results
- Altamira Therapeutics Ltd. (EARS) Income Statement Analysis – Financial Results
- L&F Acquisition Corp. (LNFA-UN) Income Statement Analysis – Financial Results
- GoldMining Inc. (0UYN.L) Income Statement Analysis – Financial Results
- ECP Environmental Growth Opportunities Corp. (ENNVU) Income Statement Analysis – Financial Results
ESSA Bancorp, Inc. (ESSA)
About ESSA Bancorp, Inc.
ESSA Bancorp, Inc. operates as a bank holding company for ESSA Bank & Trust that provides a range of financial services to individuals, families, and businesses in Pennsylvania. The company accepts savings accounts, interest bearing demand accounts, checking accounts, money market accounts, club accounts, certificates of deposit and IRAs, and other qualified plan accounts, as well as commercial checking accounts. Its loan portfolio includes first mortgage loans for the purchase, construction, or refinancing of one- to four-family residential real estate property; commercial real estate loans; home equity loans and lines of credit; and commercial and other consumer loans, as well as loans secured by deposits and personal unsecured loans. In addition, the company offers insurance benefits consulting services, such as health insurance, life insurance, short term and long term disability, dental, vision, 401(K) retirement planning, and individual health products, as well as asset management and trust, and investment services. As of September 30, 2021, it operated 21 community offices, including seven offices in Monroe County, three offices in Lehigh County, five offices in Northampton County, one office in Lackawanna County, one office in Luzerne County, one office in Chester County, two offices in Delaware County, and one office in Montgomery County, Pennsylvania. The company was founded in 1916 and is headquartered in Stroudsburg, Pennsylvania.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.84M | 69.30M | 68.22M | 64.39M | 61.46M | 55.17M | 56.05M | 53.72M | 55.72M | 51.69M | 47.32M | 47.87M | 35.80M | 35.22M | 34.66M | 34.79M | 32.03M | 27.20M | 5.82M | 5.83M | 21.16M | 4.38M | 4.38M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 67.84M | 69.30M | 68.22M | 64.39M | 61.46M | 55.17M | 56.05M | 53.72M | 55.72M | 51.69M | 47.32M | 47.87M | 35.80M | 35.22M | 34.66M | 34.79M | 32.03M | 27.20M | 5.82M | 5.83M | 21.16M | 4.38M | 4.38M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 28.54M | 27.70M | 26.81M | 26.99M | 24.66M | 24.45M | 24.18M | 25.29M | 24.79M | 21.73M | 19.92M | 19.95M | 19.13M | 18.50M | 17.77M | 17.15M | 12.65M | 10.83M | 9.19M | 9.04M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 680.00K | 648.00K | 767.00K | 636.00K | 481.00K | 699.00K | 903.00K | 1.14M | 1.06M | 974.00K | 633.00K | 574.00K | 415.00K | 658.00K | 626.00K | 672.00K | 630.00K | 695.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.22M | 28.35M | 27.57M | 27.62M | 25.14M | 25.15M | 25.08M | 26.43M | 25.85M | 22.71M | 20.56M | 20.52M | 19.54M | 19.16M | 18.40M | 17.82M | 13.28M | 11.52M | 9.19M | 9.04M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | -74.58M | -12.70M | -72.11M | -69.00M | -65.27M | -56.23M | -12.92M | -13.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.00K | 0.00 | 0.00 | 9.97M | 5.29M | -4.14M | 14.86M | 14.86M |
| Operating Expenses | 42.12M | -46.23M | 4.28M | -44.49M | -43.86M | -40.13M | -27.59M | 4.02M | 3.59M | 2.96M | 2.52M | 2.44M | 1.78M | 2.15M | 2.12M | 2.05M | 2.06M | 1.51M | 19.17M | 14.33M | -4.14M | 14.86M | 14.86M |
| Cost & Expenses | 42.12M | -46.23M | 4.28M | -44.49M | -43.86M | -40.13M | -27.59M | 4.02M | 3.59M | 2.96M | 2.52M | 2.44M | 1.78M | 2.15M | 2.12M | 2.05M | 2.06M | 1.51M | 19.17M | 14.33M | -4.14M | 14.86M | 14.86M |
| Interest Income | 0.00 | 85.50M | 62.81M | 58.69M | 64.07M | 67.76M | 64.50M | 58.32M | 58.37M | 54.18M | 50.78M | 51.10M | 45.20M | 47.18M | 49.26M | 52.73M | 52.07M | 45.51M | 36.45M | 31.92M | 28.81M | 29.07M | 29.07M |
| Interest Expense | 11.86M | 23.95M | 3.04M | 5.79M | 15.87M | 20.75M | 16.27M | 12.80M | 11.43M | 10.39M | 10.63M | 11.26M | 16.13M | 18.28M | 21.31M | 23.74M | 25.64M | 23.81M | 19.22M | 14.32M | 11.93M | 12.22M | 12.22M |
| Depreciation & Amortization | 0.00 | 2.12M | 2.18M | 2.19M | 2.21M | 1.39M | 1.65M | 1.95M | 2.22M | 637.00K | 960.00K | 990.00K | 436.00K | 135.00K | 1.23M | 1.20M | 1.25M | 1.05M | 1.06M | 969.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | 0.00 | 25.19M | 27.19M | 22.08M | 19.81M | 16.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.71M | 25.55M | 0.00 | 0.00 | 0.00 | 17.02M | 19.23M | 19.23M |
| EBITDA Ratio | 0.00% | 33.56% | 41.46% | 31.32% | 29.08% | 27.82% | 53.72% | 44.08% | 43.37% | 48.56% | 51.23% | 52.33% | 49.72% | 75.57% | 83.35% | 97.86% | 112.53% | 75.42% | 447.70% | 362.30% | 80.45% | 439.43% | 439.43% |
| Operating Income | 20.96M | 23.07M | 28.05M | 19.90M | 17.60M | 15.04M | 28.46M | 23.03M | 23.40M | 24.46M | 23.28M | 24.06M | 17.37M | 26.48M | 27.66M | 32.85M | 34.79M | 19.46M | 24.98M | 20.16M | 17.02M | 19.23M | 19.23M |
| Operating Income Ratio | 30.90% | 33.29% | 41.11% | 30.90% | 28.63% | 27.26% | 50.78% | 42.88% | 42.00% | 47.33% | 49.21% | 50.26% | 48.50% | 75.19% | 79.81% | 94.42% | 108.61% | 71.55% | 429.43% | 345.69% | 80.45% | 439.43% | 439.43% |
| Total Other Income/Expenses | 0.00 | -4.41M | -3.62M | -4.28M | -5.80M | -3.43M | -5.25M | -4.47M | -6.55M | -5.70M | -4.81M | -4.22M | 248.00K | 0.00 | 0.00 | -68.00K | -802.00K | -4.34M | -20.28M | -130.00K | 0.00 | -12.22M | 17.49M |
| Income Before Tax | 20.96M | 23.07M | 25.00M | 19.90M | 17.60M | 15.04M | 12.20M | 8.93M | 10.31M | 12.75M | 11.40M | 11.66M | 248.00K | 7.12M | 6.36M | 9.11M | 9.15M | -4.34M | 5.77M | 5.83M | 5.09M | 7.01M | 7.01M |
| Income Before Tax Ratio | 30.90% | 33.29% | 36.65% | 30.90% | 28.63% | 27.26% | 21.76% | 16.62% | 18.50% | 24.66% | 24.08% | 24.35% | 0.69% | 20.22% | 18.34% | 26.18% | 28.55% | -15.97% | 99.12% | 100.05% | 24.04% | 160.25% | 160.25% |
| Income Tax Expense | 3.97M | 4.49M | 4.93M | 3.47M | 3.18M | 2.42M | 5.66M | 1.59M | 2.58M | 2.95M | 2.89M | 2.83M | 33.00K | 1.86M | 1.84M | 2.55M | 3.07M | 782.00K | 1.81M | 1.38M | 1.17M | 2.31M | 2.31M |
| Net Income | 16.99M | 18.58M | 20.07M | 16.42M | 14.42M | 12.62M | 6.53M | 7.34M | 7.73M | 9.79M | 8.50M | 8.82M | 215.00K | 5.26M | 4.51M | 6.56M | 6.08M | -5.13M | 3.95M | 4.45M | 3.92M | 4.70M | 4.70M |
| Net Income Ratio | 25.05% | 26.81% | 29.42% | 25.51% | 23.46% | 22.88% | 11.65% | 13.66% | 13.87% | 18.94% | 17.97% | 18.43% | 0.60% | 14.93% | 13.02% | 18.84% | 18.97% | -18.84% | 67.96% | 76.33% | 18.50% | 107.38% | 107.38% |
| EPS | 1.78 | 1.91 | 2.06 | 1.65 | 1.39 | 1.18 | 0.60 | 0.69 | 0.74 | 0.94 | 0.79 | 0.76 | 0.02 | 0.46 | 0.36 | 0.47 | 0.39 | -0.30 | 0.23 | 0.26 | 0.23 | 0.28 | 0.28 |
| EPS Diluted | 1.78 | 1.91 | 2.06 | 1.65 | 1.39 | 1.18 | 0.60 | 0.69 | 0.73 | 0.93 | 0.79 | 0.76 | 0.02 | 0.46 | 0.36 | 0.47 | 0.38 | -0.30 | 0.23 | 0.26 | 0.23 | 0.28 | 0.28 |
| Weighted Avg Shares Out | 9.53M | 9.73M | 9.76M | 9.95M | 10.35M | 10.73M | 10.83M | 10.60M | 10.40M | 10.45M | 10.82M | 11.56M | 11.05M | 11.49M | 12.53M | 13.84M | 15.56M | 16.98M | 16.88M | 16.88M | 16.88M | 16.88M | 16.88M |
| Weighted Avg Shares Out (Dil) | 9.53M | 9.73M | 9.77M | 9.95M | 10.35M | 10.73M | 10.83M | 10.66M | 10.52M | 10.54M | 10.82M | 11.56M | 11.05M | 11.49M | 12.53M | 13.95M | 15.98M | 16.98M | 16.88M | 16.88M | 16.88M | 16.88M | 16.88M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at [email protected] or...
ESSA Pharma Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - EPIX
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at [email protected] or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed...
ESSA Bancorp, Inc. Announces Fiscal Fourth Quarter, Full Year 2024 Financial Results
STROUDSBURG, PA / ACCESSWIRE / October 23, 2024 / ESSA Bancorp, Inc. (the "Company") (NASDAQ:ESSA), the holding company for ESSA Bank & Trust (the "Bank"), a $2.2 billion asset financial institution providing full service commercial and retail banking, asset management...
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD...
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.
ESSA Bancorp, Inc. Declares Quarterly Dividend
STROUDSBURG, PA / ACCESSWIRE / August 28, 2024 / ESSA Bancorp, Inc. (NASDAQ Global MarketSM:ESSA), the holding company for ESSA Bank & Trust, today announced that its Board of Directors declared a dividend of fifteen cents ($0.15) per share. The...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the...
Source: https://incomestatements.info
Category: Stock Reports